Eyenovia Inc EYEN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/10/24 EDT
0.7713quote price arrow down-0.0333 (-4.1387%)
Volume
594,292
52 week range
0.50 - 3.97
Loading...
  • Open0.80
  • Day High0.80
  • Day Low0.77
  • Prev Close0.8046
  • 52 Week High3.97
  • 52 Week High Date05/12/23
  • 52 Week Low0.50
  • 52 Week Low Date04/10/24

Key Stats

  • Market Cap39.304M
  • Shares Out50.96M
  • 10 Day Average Volume1.30M
  • Dividend-
  • Dividend Yield-
  • Beta1.73
  • YTD % Change-62.92

KEY STATS

  • Open0.80
  • Day High0.80
  • Day Low0.77
  • Prev Close0.8046
  • 52 Week High3.97
  • 52 Week High Date05/12/23
  • 52 Week Low0.50
  • 52 Week Low Date04/10/24
  • Market Cap39.304M
  • Shares Out50.96M
  • 10 Day Average Volume1.30M
  • Dividend-
  • Dividend Yield-
  • Beta1.73
  • YTD % Change-62.92

RATIOS/PROFITABILITY

  • EPS (TTM)-0.66
  • P/E (TTM)-1.16
  • Fwd P/E (NTM)-1.09
  • EBITDA (TTM)-24.623M
  • ROE (TTM)-207.83%
  • Revenue (TTM)3,790.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-719,290.31%
  • Debt To Equity (MRQ)158.76%

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Eyenovia Inc

 

Profile

MORE
Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. It is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic...
Tsontcho Ianchulev M.D.
Executive Chairman of the Board
Michael Rowe
Chief Executive Officer, Director
Bren Kern
Chief Operating Officer
John Gandolfo
Chief Financial Officer, Secretary
Address
295 Madison Ave Ste 2400
New York, NY
10017
United States

Top Peers

SYMBOLLASTCHG%CHG
INTS
Intensity Therapeutics Inc
4.00+0.24+6.38%
GANX
Gain Therapeutics Inc
2.51-0.03-1.18%
AVRO
AVROBIO Inc
1.23-0.02-1.60%
IMRX
Immuneering Corp
1.45-0.11-7.05%
QTTB
Q32 Bio Inc
27.13+0.33+1.23%